Vesicular monoamine transporter-2 and aromatic l-amino acid decarboxylase enhance dopamine delivery after L-3,4-dihydroxyphenylalanine administration in parkinsonian rats

Journal of Neuroscience

Volumn 19, Issue 8, 1999, Pages 3266-3274

  Lee, Won Yong ^a,b   Chang, Jin Woo ^a,c   Nemeth, Nicole L ^a   Kang, Un Jung ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

AADC; Dopamine; Gene therapy; L DORA; Parkinson's disease; Short duration response; VMAT; Wearing off

Indexed keywords

AMINO ACID DECARBOXYLASE; CARRIER PROTEIN; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSFORMATION; CELL TRANSPLANTATION; DOPAMINE BRAIN LEVEL; GENE THERAPY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; SKIN FIBROBLAST; SYNAPSE VESICLE;

EID: 0033560875     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.19-08-03266.1999     Document Type: Article

References (56)

1. Amara S (1995) Monoamine transporters: basic biology and clinical implications. Neuroscience 1:259-268.
2. Bencsics C, Wachtel SR, Milstien S, Hatakeyama K, Becker JB, Kang UJ (1996) Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts. J Neurosci 16:4449-4456.
3. Birkmayer W, Hornykiewicz O (1961) Der L-3, 4-Dioxyphenylalanin (= DOPA) effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73:787-788.
4. Chang J-W, Wachtel SR, Young D, Rang UJ (1999) Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forehrain bundle and striatal lesions. Neuroscience 88:617-628.
5. Cooper JR, Bloom FE, Roth RH (1996) The biochemical basis of neuropharmacology. New York: Oxford UP.
6. CotziasCG, Van Woert M H, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276:374-379.
7. Cubclls JF, Rayport S, Rajcndran G, Sulzer D (1994) Methamphetamine neurotoxicity involves vacuolation of cndocytic organelles and dopamine-dependcnt intraccllular oxidative stress. J Ncurosci 14:2260-2271.
8. + uptake into synaptic dopaminc vesicles: possible involvement in MPTP neurotoxicity. Br J Pharmacol 109:411-414.
9. During MJ, Nacgclc JR, O'Mallcy KL Geller AI (1994) Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosinc hydroxylasc. Science 266:1.399-1403.
10. Engber TM, Boldry RC, Kuo S, Chase TN (1992) Dopaminergic modulation of striatal neuropeptides: differential effects of D, and IX receptor stimulation on somatostatin, neuropeplide Y. neurotensin. dynorphin and enkephalin. Brain Res 581:261-268.
11. Erickson JD, Eiden LE (1993) Functional identification and molecular cloning of a human brain vesicular monoamine transporter. J Neurochem 61:2314-2317.
12. Erickson JD, Eiden LE, Huffman BJ (1992) Expression cloning of a rcserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci USA 89:10993-10997.
13. Erickson JD, Schafer M K, Bonner TL, Eiden LE, Weihe E (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 93:5166-5171.
14. Fabbrini G, Juncos J, Mouradian MM, Scrrati C, Chase TN (1987) Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 21:370-376.
15. Fisher LJ, Jinnah HA, Kale LC, Higgins GA, Gage FH (1991) Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-DOPA. Neuron 6:371-380.
16. Furukawa Y, Shimadzu M, Rajput AH, Shimizu Y, Tagawa T, Mori H, Yokochi M, Narabayashi H, Hornykiewicz O, Mizuno Y, Kish SJ (1996) GTP-cyclohydrolasc I gene mutations in hereditary progressive and dopa-responsivc dystonia. Ann Neurol 39:609-617.
17. Gasnier B, Krejci E, Bottom D, Massoulie J, Henry J-P (1994) Expression of a bovine vesicular monoamine transporter in COS cells. FEBS Lett 342:225-229.
18. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432.
19. 3H]flunitrazepam. Ncuroscicnce 57:673-681.
20. Hadjiconstantinou M, Rossetti ZL, Wemlingcr TA, Neff NH (1995) Dizocilpine enhances striatal tyrosinc hydroxylasc and aromatic i.-amino acid decarboxylase activity. Eur J Pharmacol Mol Pharmacol Sect 289:97-101.
21. Hattori T, McGeer PL, McGeer EG (1979) Dendro axonic neurotransmission. II. Morphological sites for the synthesis, binding and release of neurotransmittcrs in dopaminergic dendrites in the substantia nigra and cholinergic dendrites in the neostriatum. Brain Res 170:71-83.
22. Henry JP, Button D, Sagne C, Isambert MF, Desnos C, Blanchard V, Raisman-Vozari R, Krejci E, Massoulie J, Gasnier B (1994) Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J Exp Biol 196:251-260.
23. Hoshimaru M, Ray J, Sah DWY, Gage FH (1996) Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myc oneogene. Proc Natl Acad Sci USA 93:1518-1523.
24. Ichinose H, Ohye T, Takahashi E, Scki N, Hori T, Segawa M, Nomura Y, Endo K, Tanaka H, Tsuji S, Fujita K, Nagatsu T (1994) Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in Ihc GTP cyclohydrolase 1 gene. Nat Genet 8:236-242.
25. Rang UJ, Fisher LJ, Job TH, O'Mallcy KL, Gage FH (1993) Regulation of dopamine production by genetically modified primary fihroblasts. J Neurosci 13:5203-5211.
26. Lamprecht F, Coyle JT (1972) DOPA dccarhoxylase in the developing nil brain. Brain Res 41:503-506.
27. Leff SE, Rcndahl KG, Spratt SK, Rang UJ, Mandel RJ (1998) In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTP cyclohydrolase I with tyrosinc hydroxylase. Exp Neurol 151:249-264.
28. Lindvall O, Sawlc G, Widncr H, Rothwcll JC, Björklund A, Brooks D, Brundin P, Frackowiak R, Marsden CD, Odin P, Rehncrona S (1994) Evidence for long-term survival and function of dopamincrgic grafts in progressive Parkinson's disease. Ann Ncurol 35:172-180.
29. + toxicity. Brain Res Mol Brain Res 25:90-96.
30. + toxicity encodes a vesicular amine transporter. Cell 70:539-551.
31. Mahala SK, Mahata M, Fisher-Colbrie R, Winkler H (1993) Vesicle monoaniine transporters 1 and 2: differential distribution and regulation of their mRNAs in chromaflrin and ganglionic cells of rat adrenal medulla. Neurosci Lett 156:70-72.
32. Mandel RJ, Rendahl SK, Spratt SK, Snydcr LK, Cohcn LK, Leff SE (1998) Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosinc hydroxylase and human GTP-cyclohydrolase 1 in a rat model of Parkinson's disease. J Neurosci 18:4271-4284.
33. Marsden CD ( 1994) Parkinson's disease. J Neurol Ncurosurg Psychiatry 57:672-681.
34. Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1:345-349.
35. Mattioli R, Schwarting RKW, Huston JP (1992) Recovery from unilateral 6-hydroxydopamine lesion of substantia-nigra promoted by the ncurotachykinin substance P-1-11. Neuroscience 48:595-605.
36. Melarned E (1988) Brain grafting may reverse loss of responsiveness to levodopa therapy in Parkinson's disease. Clin Neuropharmacol 11:77-82.
37. Mercer L, del Fiacco M, Cucllo AC (1979) The smooth endoplasmic rcticulum as a possible storage site for dendritic dopamine in substantial nigra neurons. Experientia 35:101-103.
38. Merickel A, Rosandich P, Peter D, Edwards RH (1995) Identification of residues involved in substrate recognition by a vesicular monoamine transporter. J Biol Chem 270:25798-25804.
39. Misawa H, Takahashi R, Deguchi T (1994) Calcium-independent release of acctylcholine from stable cell lines expressing mouse cholinc acetyltransferase cDNA. J Neurochem 62:465-470.
40. Mouradian MM, Heuser IJ, Baronti F, Chase TN (1990) Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Purkinson's disease. Ann Neurol 27:18-23.
41. Nirenberg MJ, Chan J, Liu Ye Edwards RH, Pickel VM (1996) Ultrastructural localisation of the vesicular monoamine transporter-2 in midhrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci 16:4135-4145.
42. Nutt JGm Holford NHG (1996) The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 39:561-573.
43. Nutt JG, Woodward WR, Carter JH, Gancher ST (1992) Effect of long-term therapy on the pharmacodynamies of levodopa. Arch Neurol 49:1123-1130.
44. Nygaard TG, Takahashi H, Heiman GA, Snow BJ, Fahn S, Calne DB (1992) Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with doparesponsive dystonia. Ann Neurol 32:603-608.
45. Papa SM, Engber TM, Kask AM, Chase TN (1994) Motor fluctuations in Ievodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662:69-74.
46. Peppe A, Damhrosia JM, Chase TN (1993) Risk factors for motor response complications in L-DOPA-treated parkinsonian patients. Adv Neurol 60:698-702.
47. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, Edwards RH (1995) Differential expression of two vesicular monoamine transporters. J Neurosci 15:6179-6188.
48. Rupperl C, Sandrasagra A, Anton B, Evans C, Schweitzer ES, Tobin AJ (1993) Rat-1 fibrohlasts engineered with GAD65 and GAD67 cDNAs in retroviral vectors produce and release GABA. J Neurochem 61:768-771.
49. 18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol 31:166-173.
50. Shoulson I, Glaubiger GA, Chase TN (1975) On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25:1144-1148.
51. Sulzer D, St Remy C, Rayport S (1996) Reserpine inhibits amphetamine action in ventral midbrain culture. Mol Pharmacol 49:338-342.
52. Takahashi N, Miner LL, Sora I. Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, Uhl GR (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94:9938-9943.
53. von Grafenstein H, Borges R, Knight DE (1992) The effect of botulinum toxin type D on the triggered and constitutive exocytosis/endocytosis cycles in cultures of bovine adrenal medullary cells. FEBS Lett 298:118-122.
54. Wachtel SR, Ahercrombie ED (1994) 1-3,4-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63:108-117.
55. Wachtel SR, Bencsics C, Kang UJ (1997) The role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. J Neurochem 69:2055-2063.
56. Zhu M-Y, Juorio AV (1995) Aromatic L-amino acid decarboxylase: biological characterization and functional role. Gen Pharmacol 26:681-696.